Study/Projects - HIV

ACCELERATE

Post Date: 
2022-09-08
   |   
Countries: 
Under the directives of PEPFAR, with support from USAID, and in collaboration with NACO, the ACCELERATE program provides HIV/AIDS services for high-risk populations including key populations affected by HIV throughout India and technical assistance (TA) to the national, state, and district...

Mitr Clinic - Pride and Beyond

Post Date: 
2022-09-08
USAID and PEPFAR supported Program ACCELERATE, implemented by Johns Hopkins University School of Medicine (JHU SOM) in partnership with YRG Care, The Fenway Institute and the Blue Lotus Advisory under the leadership of National AIDS Control Organisation (NACO) and State AIDS Control Societies (SACS...

Kidaba Thawai (Fearless Souls) Documentary

Post Date: 
2022-09-08
   |   
Countries: 
The documentary Kidaba Thawai is based on ACCELERATE's intervention - an Adolescent Friendly Health Center (AFHC) in Imphal, Manipur. The documentary discusses AFHC's comprehensive health care delivery model (HIV and non-HIV services) which contributes to the holistic development of adolescents. A...

“Bridging the Gaps”: Understanding the Barriers and Facilitators in the Tuberculosis Prevention Care Cascade for Optimizing Isoniazid Preventive Therapy Uptake among Adults Living with HIV in India, a Mixed-Method Approach

Post Date: 
2021-11-02
   |   
Countries: 
   |   
Clinical Sites: 
PURPOSE: The isoniazid preventive therapy policy has achieved limited success in low and middle-income countries. With limited empirical research exploring the barriers to suboptimal IPT uptake, it is important to understand this knowledge gap. Also, limited programmatic strategies exist to address...

A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Post Date: 
2021-06-15
   |   
Countries: 
   |   
Clinical Sites: 
Primary Hypothesis A 3-month regimen of rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) with clofazimine (CFZ) dosed as 100 mg daily with a 2-week 300 mg daily loading dose (Arm 1) will demonstrate early efficacy (time to 12-week liquid culture conversion) relative to standard of care (SOC) (...

P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum

Post Date: 
2021-05-18
   |      |   
Clinical Sites: 
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women, studied the PK of more than 25 HIV and TB drugs in these women and published 27 manuscripts presenting these data. P1026s data was cited in 32% of the 76 perinatal...

The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)

Post Date: 
2021-04-26
   |      |   
Clinical Sites: 
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of moxifloxacin and clofazimine in children are urgently needed to inform their current and future use in children with Rifampicin-Resistant TB (RR-TB). Both medications have a key...

Effect of Neighborhoods and Peer Networks on substance use and violence among adolescents living with and without HIV in India

Post Date: 
2021-01-28
   |   
Countries: 
   |   
Clinical Sites: 
Purpose of the study: A strong bidirectional association exists between substance use, various forms of violence and HIV. Substance use accounts for 0.8% of the burden of disease measured in disability adjusted life years (DALYs) among adolescents in South Asia. Violence among adolescents living...

Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)

Post Date: 
2020-12-05
   |   
Countries: 
   |   
Clinical Sites: 
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not develop active TB enrolled in ACTG 5274 and ACTG 5279 Study Design: Longitudinal antibody responses will be examined among select participants in A5274 who have plasma samples...

Prevalence of Risk Factors for Lung Cancer and Facilitators and Barriers for Tobacco Cessation among People Living with HIV

Post Date: 
2020-04-01
   |   
Countries: 
   |   
Clinical Sites: 
India has the world’s third largest HIV epidemic, with 2.1 million people currently living with HIV and an additional 90,000 new infections each year.[29] At the same time, expansion of the HIV response under India’s premier governmental agency - the National AIDS Control Organization (NACO), has...

The Sentinel Research Network of IeDEA: A Prospective Cohort among People Living with HIV

Post Date: 
2020-03-12
   |   
Clinical Sites: 
This study is nested within the TREAT Asia HIV Observational Database initiative. The global scale up of antiretroviral therapy (ART) has significantly improved the immune recovery and life expectancy of people living with HIV (PLHIV). However, PLHIV on long-term ART now face health challenges...

Hybrid Trial for Alcohol Reduction among People with TB and HIV in India

Post Date: 
2020-02-12
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Geetanjali Chander is PI and Dr. Kakrani is local site PI at DY Patil Medical College for this study. The highest incidence of tuberculosis disease (TB) in the world is in India, accounting for 27% of all new cases globally, with approximately 86,000 among persons with HIV (PWH). Unhealthy...

Pregnancy Associated Immune Responses to Tuberculosis and HIV in India and South Africa (PARTHISA)

Post Date: 
2020-01-14
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jyoti Mathad is Co-PI of this study. Purpose: Tuberculosis (TB) is a leading cause of maternal mortality, especially among HIV-infected women. Women are most likely to develop active TB during and immediately after pregnancy. The immunologic conditions responsible for this phenomenon are not...

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

Post Date: 
2019-12-30
Learn more about this effort to foster development of long-lasting therapies for illnesses that require taking medications long-term

Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

Post Date: 
2019-12-11
   |   
Countries: 
   |   
Clinical Sites: 
Objectives/Aims We will compare the degree of lung impairment between HIV-TB co-infected adults (HIV-TB group) and TB cases without HIV co-infection (TB group) who successfully complete TB therapy. We hypothesize that the HIV-TB group will have a greater degree of lung...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB...

Visual Field Loss in HIV-Positive Patients of Non-Infectious HIV Retinopathy

Post Date: 
2019-06-02
   |   
Countries: 
   |   
Clinical Sites: 
New study will assess HIV+ patients and determine the prevalence of visual field loss due to noninfectious HIV retinopathy

Immune Correlates of LTBI in HIV-exposed Infants

Post Date: 
2019-04-29
   |   
Countries: 
About 2 billion people worldwide harbor asymptomatic latent TB infection (LTBI), activation of which results in progression to TB disease. In areas of high tuberculosis (TB) prevalence, infants and young children have a 3-fold higher risk of progression and death from TB at age < 5 years...

P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”

Post Date: 
2019-02-06
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated September 2, 2021 Full Title: P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “...

Pages